Reports Search

Special index page with links to over 35 editions of GHF, including a series of exclusive stories, guest essays, interviews, podcasts from the second quarter of 2024 between April and June, compiled by Sana Ali.

Group 1 'Treaty talks' comprises posts regarding the WG IHRs and the INB for a pandemic agreement. See in particular the posts regarding the politics of the Africa position and various reports regarding pathogen access and benefit sharing, financing, 'equity', and technology transfer.

Group 2 includes a range of posts, including comments on WHA77 and WHO financing (the 'investment round').

Group 3 includes a number of guest essays, including One Health and PABS in the draft pandemic agreement

While this week’s CARICOM summit in Grenada has been postponed due to Hurricane Beryl, when it does convenes, a key item on the agenda will be the new ‘HeDPAC’ initiative to deepen South-South partnerships to meet shared global health challenges – from pandemic threats to climate change.

In remote communities of Guyana, the introduction of new satellite technology is enabling freshly trained community health workers to get patients an accurate diagnosis and rapid, appropriate treatment in ways unimaginable only a few years ago.  

In Rwanda, meanwhile, the government’s achievement in getting the COVID-19 vaccine innovator, BioNTech, to set up its first mRNA manufacturing facility in Kigali is a success story that small island states in the Caribbean would love to emulate. 

The World Trade Organization (WTO) Trade-Related Aspects of Intellectual Property Rights (TRIPS) Council will meet on 10-11 July. On the agenda is the review of the implementation of the TRIPS Agreement under TRIPS Article 71.1, as proposed by Colombia. It would be the first time such a review is taking place in the 30 years that the TRIPS Agreement has been in force.

In recent days, access to medicines activists in many parts of the world are grappling with developments that have struck at the heart of the movement.

Médecins Sans Frontières, arguably one of the most powerful, influential and well-funded activist organization in the space, has proposed a restructuring its well-regarded and highly admired Access Campaign that currently works all over the world in the most political and challenging settings and one that consistently led and expanded the access to medical products for a range of diseases. MSF has programmes in more than 75 countries across the world.

From ensuring treatments, to challenging patents, from fighting for lower prices of drugs, to working with governments silently to improve health outcomes, the Access Campaign has been at the frontier of not only taking on the might of the pharmaceutical industry, but also making states more accountable.

1. The Kyoto Biennial Conference of the International Law Association was convened remotely as in December 2020 the COVID-19 pandemic precluded in-person gatherings. The Lisbon Biennial in July 2022 was among the first in-person events attended by many of its participants as the shadow of the pandemic dissipated. As the ILA prepares for its Athens Biennial in June 2024 the international community has largely returned to “normalcy” from a public health standpoint. Yet unfinished business from the COVID-19 pandemic remains as we seek to lay the groundwork for preventing and mitigating future pandemics. In a paradoxical sense, the COVID-19 pandemic opened a window of opportunity for governments and civil society to put in place institutional mechanisms to accomplish these objectives. Yet that window may not remain open for long. Planning and spending time to address low probability, high risk events – paradigmatically pandemics -- does not occupy a high government priority because returns on investment are uncertain, and political leaders are not likely to be credited by their constituencies for spending to address uncertainties.

While the World Health Organization’s International Negotiating Body (INB) continues to negotiate a global Pandemic Agreement, the US has issued its own vision for global health security and expanded its bilateral partnerships with countries across the world.

Following the release of this revamped US global health security strategy, Health Policy Watch spoke with Stephanie Psaki, the inaugural US Coordinator for Global Health Security and Deputy Senior Director for Global health security and biodefense at the US National Security Council.

More from interview here

See also U.S. GOVERNMENT GLOBAL HEALTH SECURITY STRATEGY 2024

The most recent estimate of the global number of deaths from dog-mediated rabies is 59 000 per year.1 Rabies is associated with a 99.9% fatality rate and severe trauma in families in which a rabies death occurs, and remains a major public health concern in most of Africa and Asia and some parts of South America. In the Americas, dog-mediated rabies is still a public health issue in specific regions in some countries.2 Robust data on rabies are lacking for many countries. The information available to WHO is presented on Map 1.

Ending human deaths from dog-mediated rabies by 2030 (“Zero by 30”) is the goal of a global strategy agreed in 2015 by a cross-sectoral partnership composed of WHO, the Food and Agriculture Organization of the United Nations, the World Organisation of Animal Health (WOAH) and the Global Alliance for Rabies Control.3 In 2020, as partnerships are vital to making progress towards Zero by 30, United Against Rabies (UAR) was launched as a collaborative forum for public and private sector organizations, rabies experts, development partners and civil society to work to improve rabies control.4

A third U.S. farmworker infected with bird flu is the first to experience respiratory symptoms

In light of H5N1 outbreak, U.S. in talks with mRNA vaccine makers on bird flu

Wastewater testing specifically for bird flu virus will scale up nationally in coming weeks

When should we start making H5N1 vaccine, and who will make that decision? In short, it’s complicated

USDA, FDA turf battles hamper responses to outbreaks like H5N1 bird flu

"MSF welcomes these new amendments to the IHR as an important first step towards addressing inequity in access to medical care and health products during global health emergencies. As a medical humanitarian organisation responding to emergencies globally, we are encouraged to see explicit recognition of the need to ensure access to health products during health emergencies, including in humanitarian settings.

“As the INB negotiation is extended for another year, we urge WHO member states to remember the clear lessons learned from the past health emergencies, from Ebola virus disease to COVID, follow the example of the IHR amendments, and complete the package of measures needed for a just framework for pandemic prevention, preparedness and response. 

More

With the first-ever malaria vaccines rolling out across Africa and a next-generation tuberculosis (TB) vaccine in testing, scientific advances are driving an unparalleled expansion of vaccine development. But vaccines in development don’t become immunizations that protect our health without concerted efforts by global initiatives like Gavi, the vaccine alliance, that help bring these life-saving products to the world’s poorest countries.

Next month, Gavi will kick-off a campaign to raise several billion dollars to deliver on its new strategy. The stakes are high: falling short of its target could delay delivery of vaccines to those most in need.